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ABSTRACT 
Leishmaniasis is a vector-borne zoonotic infection caused by an obligate intra macrophage protozoan parasite ‘Leishmania’. Despite of a number of 
remedies available, leishmaniasis is still a speedy migrating and deadly infection due to the resistance of the parasite to the drugs as well as their 
toxicity. Hence, there is a need for targeted drug delivery system for enhancing the systematic effect of antileishmanial drugs. Although the number 
of antileishmanial drugs in a variety of dosage forms is available, there is an urgency to develop more efficient, cost-effective and safe therapy, 
which can be achieved by macrophage targeting utilizing passive (phagocytosis), and/or active (receptor mediated) strategies utilizing nano-
formulations. Positive considerations of various factors like the enhanced permeation and retention (EPR) effect, size, and charge of nano-
formulations can facilitate the passive targeting, and various receptors like lectin receptor, mannose receptor, mannosyl-fucosyl receptor, scavenger 
receptor, etc on the macrophage surface may play an important role in active drug targeting. Also, monoclonal antibody, interferon’s, tufstin are 
other agents which have been broadly utilized for targeting. 
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INTRODUCTION 
This review provides a current perspective on the challenges and 
possibilities in the macrophage targeting. It summarizes recent 
important and interesting articles investigating the challenging 
treatment of the parasitic infection, leishmaniasis. In addition, it 
compares and contrasts targeting strategies for leishmaniasis. We 
retrospectively reviewed all articles from 1950 to 2015 focused on 
Leishmaniasis, by searching in the Pub Med database, Science direct, 
wiley online library on each of the following keywords: ‘Leishmania’, 
‘macrophage targeting’, ‘drug delivery systems’, ‘drugs ‘life cycle’, 
‘conventional therapy’, ‘kala-azar’, ‘receptor’, ‘nano-formulations’, in 
association with ‘leishmaniasis’. After vast literature survey and 
selection procedure, this article comes into form discussing the 
issues, and future possibilities in the treatment of leishmaniasis 
Leishmaniasis represents an assembly of diseases with clinical and 
epidemiological diversities. It encompasses a range of clinical 
manifestations that initiate from simple self-limiting, self-healing or 
asymptomatic cutaneous ulcers and may proceed to horribly 
disfigure, debilitating mucocutaneous and lethal visceral form if 
remains untreated [1]. Leishmaniasis is a vector born zoonotic 
infection caused by obligate intra macrophage protozoan parasite 
‘leishmania’ in the mammalian hosts and spreads by carrier female 
sand fly. Despite of a number of remedies available, leishmaniasis is 
still a speedy migrating deadly infection, which is broadly attributed 
to the resistance of the parasite to drugs as well as their toxicity. 
Besides, intersection with human immunodeficiency virus (HIV) 
with a predictable increase in treatment failures, and large-scale 
resistance to antimonial has generated an urgency to develop more 
efficient panacea. Further, in this context chemotherapy has been 
hampered by localization of parasites within lysosomal vacuoles of 
the macrophages, restricting the bioavailability of many potential 
antileishmanial compounds.  
Lacuna in the treatment regimen provokes to generate a therapy 
that is cheaper, requires a minimal dose of drugs and specific to its 
site of action. Since, the causative agent of the disease, an 
intracellular parasite harbour in macrophages and specific tissue 
sites, which can be the target of the drug, the targeted drug delivery 
system is the need of the day [2].  
Various leishmania species infect macrophages and dendritic cells of 
the host immune system, causing symptom ranging from disfiguring 
cutaneous and mucocutaneous lesions, widespread destruction of 
mucous membranes, or visceral disease affecting the haemopoetic 
organs of the host. This infection can be broadly classified into three 
clinical syndromes namely cutaneous leishmaniasis (oriental sore), 
mucocutaneous leishmaniasis (espundia) and visceral leishmaniasis 
(VL, kala-azar). Other forms are posted kala-azar dermal 
leishmaniasis, viscerotropic leishmaniasis and diffuse cutaneous 
leishmaniasis. Clinical manifestation of the disease depends on the 
species (Leishmania donovani, L. infantum or L. major) involved.  
Host–parasite interaction: life cycle of leishmania parasite 
Stage 1: Development of amastigote in sandfly 
L. donovoni, the causative agent of Leishmaniasis, is an obligate 
parasite which is carried by the bloodsucker adult female sandfly 
from the infected mammalian host. Inside the midgut of the sandfly, 
the amastigote form of this parasite multiplies within 4-25 d via 
binary fission and finally transforms into promastigote. 
Promastigote live extracellularly in the alimentary canal of the 
sandfly, reproduces asexually and migrates to the proximal end of 
the gut for transmission to the mammalian host. The life cycle of L. 
donovani is represented schematically in fig. 1. 
Stage 2: Development of promastigote in mammalian host 
Host invasion involves attachment to macrophages, phagocytosis, 
and development inside the phagolysosome. Promastigotes enters 
the mammalian host along with the sandfly’s saliva out of which 
some are destroyed, and the others are phagocytosed by the 
macrophages. The parasite resides intracellularly in the 
parasitophorous vacuoles of the macrophages, an acid and lytic 
compartment presenting the hostile ecological niche. The host 
macrophage phagocytes the promastigotes via receptor-mediated 
endocytosis where phagosome forms phagolysosome, after fusion 
with the lysosomes. Various macrophage receptors involved in the 
entry of promastigotes are the mannose-fucose receptors, receptors 
for advanced glycosylation end products (AGE), fibronectin 
receptors, Fc receptors (FcR) and the complement receptors CR1 
and CR3 [3]. During the later phase, promastigotes (the extracellular 
form) differentiate into amastigotes (the intracellular form) thus 
adapting to live in the hydrolytic environment of the lysosome. It has 
been proposed that L. donovani after a certain extent of the 
reproduction, lyse their host cell owing to the sheer pressure of the 
mass, but few speculations also claim that they are able to leave via 
exocytosis. In vivo studies indicate that once inside macrophages, 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491                 Vol 8, Issue 2, 2016 
Kashaw et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 2, 16-26 
 
17 
promastigotes start to differentiate into amastigotes only when 
exposed to the acidic environment, and this occurs after infected 
phagosomes fuse with late endosomes. These amastigotes invade 
the other macrophages, utilizing various mechanisms of immune 
evasion like down-regulation of the parasite antigen presentation 
via major histocompatibility complex (MHC) Class II pathway, 
inhibition of oxidative burst, etc. This parasite causes the systemic 
infection of the entire reticuloendothelial system (RES), liver and spleen. 
Some of the free amastigotes are taken up by the sandfly in their blood 
meal and thus the cycle continues [4-7]. The parasite is presented to the 
T cells in draining lymph nodes via dendritic cells from the infected site 
[8]. Multiplication of the amastigotes in the macrophages takes place 
until the release occurs by a burst of macrophages. 
Cons with the current therapies being practiced in management 
of leishmaniasis 
Leishmaniasis has been mainly controlled by chemotherapy. 
Pentavalent antimonials exploited since the last 6-7 decades for the 
treatment of leishmaniasis have long been the mainline treatment, 
but, are now not very effective due to protozoal resistance. 
Moreover, the side effects of currently available antimicrobials and 
increasing cases of resistance of Leishmania to the antimonials and 
pentamidine have turned the situation to be more complicated. Over 
the past decade, although alternative drugs or new formulations of 
other standard drugs have become available and some other drugs 
are under clinical trials, the problem is still critical, and an effective 
approach is yet to be sorted out. 
 
 
Fig. 1: Schematic representation of life cycle of Leishmania 
 
Recently, a success has been the introduction of Paromomycin (an 
aminoglycoside antibiotic) but still there is the need to provide a 
better therapeutic index and to reduce side effects. Furthermore, the 
aim to develop a single drug or formulation drug effective against all 
forms of leishmaniasis still remains a dream. In the present scenario, 
the majority of the conventional dosage forms, following 
administration, deliver the drug into the body, which ultimately 
reaches the site of action by distribution and passive diffusion, 
consequently giving rise to side effects [9]. The high drug clearance 
from the body is also a limitation of conventional drugs. Besides, the 
current treatment regimen requires a prolonged course and 
treatment is often conducted in a hospital set up. table 1 provides an 
insight to the conventional therapy regimen and also lists the 
potential toxic effects of antileishmanial drugs.  
The failure of existing conventional therapy may in part be 
attributed to lack of in vitro-in vivo co-relation. Therapy failure 
arises as the drugs which show excellent in vitro data are often 
followed by poor in vivo results. Unpredictable bioavailability, rapid 
first pass metabolism, augmented clearance are some reasons that 
may be cited as the cause of drug failure.  
Other useful drugs against leishmaniasis include Amphotericin B 
(AmB) and Miltefosine. A recent survey in Bihar (most affected place 
in India, more than 90% alone) had recorded an alarming 1,000,000 
cases with 10,000 unresponsive to Antimonials, Pentamidine, and 
Am B [10-12]. Thus, it becomes obvious to develop targeting 
strategies instrumental in providing spatial delivery of more 
effective, less resistant anti-leishmanial drugs with an interception 
of minimal side effects. 
Macrophages targeting 
Designing a system proficient in delivering selectively the drug to 
the site of action is the main aspect of drug targeting. Macrophage-
targeted drug delivery approach may serve as a promising means 
to conquer many of the aforesaid problems. Localization of 
leishmania parasite within the phagolysosome of macrophages 
restricts the bioavailability of many potentially useful 
antileishmanial drugs. Macrophages serve as host cells for these 
parasites which are able to inhibit phagosomes maturation so as to 
survive and replicate within the macrophages. Hence, it is difficult 
enough to provide access of drugs selectively to these relatively 
inaccessible sites. As a result, macrophage-specific drug delivery 
systems are the focus of interest. Therefore, it becomes imperative 
to exploit the concept of “magic bullet”, a novel concept of drug 
targeting paradigm that exploits the use of surface engineered 
vehicles for site specific delivery. Further, a targeting system 
needs to be designed keeping in view the ultimate site of action of 
drug which in the present case are macrophages. Thus, in the 
scenario, the carrier should be so conditioned that they are 
directed to buffer's cells either passively or otherwise actively.
Kashaw et al. 
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In spite of the potential benefits of targeted nano-carriers, these 
systems have some drawbacks such as the cost and stability of the 
targeting moiety. To justify the increased cost, the moiety must 
significantly increase the therapeutic efficacy of the nano vector. 
Transport systems can be designed to control the dispatch of the 
loaded drug to target areas, increasing its local concentration and 
bioavailability, while prolonging its retention, half-life, and 
effectiveness. 
Outstanding favors which can be obtained by this method are: 
improved pharmacokinetics, independence of the administration 
method, minimization of required amount of the drug and its side 
effect and hence the cost of the therapy. Such researched novel drug 
delivery systems loaded with anti-leishmanial drugs are cited in 
table 2. One further drawback of targeted delivery is the effect the 
uptake pathway may have on these systems. The targeting moiety 
has to be specific to the area of interest. 
 
Table 2: Drug delivery systems studied for the delivery of antileishmanial drugs 
Drug delivery system Drug encapsulated Parasite studied References 
Liposomes Antimonial L. Donovani, L. Major [41] 
 Camptothecin L Donovani [34] 
 Pentamidine L. Donovani [42] 
 Miltefosine L. Donovani [45] 
 Atovaquone L. Donovani [46] 
Niosomes Amphotericin B L. Donovani [47] 
 Sodium stibogluconate L. Donovani [48-51] 
Microparticle Sodium stibogluconate L. Donovani [52] 
 Amphotericin B L. Infantam [53,54] 
 Doxorubicin  [55] 
Nanoparticle Amphotericin B L. Donovani (In-vitro) [38, 56] 







 Primaquine L. Donovani [24] 
Nanosuspension Amphotericin B L. Donovani (oral) [59] 
 Aphidicolin L. Donovani (In-vitro) [60] 
Solid lipid nanoparticles Amphotericin B L. Donovani [61] 
Emulsion Amphotericin B L. Donovani [62-65] 
 Amphotericin B L. Donovani [62-65] 
 Piperine L. Donovani [43] 
 Sodium stibogluconate L. Donovani [66] 
 Sitamaquine L. Major (topical) [67] 
Drug conjugate Sodium stibogluconate L. Donovani  [68] 
 Amphotericin B L. Major [69] 
 8-aminoquinoline L. Donovani [70] 
 
Concept of passive targeting 
Immunological response to foreign moiety is the natural 
phenomenon of the body which can be utilized for the passive 
targeting mediated by the invasion of the drug and drug carrier 
systems on the basis of their physicochemical properties. Particles 
uptake by the cells of the RES is an excellent example of the passive 
targeting. The endeavor potential of macrophages for rapid 
recognition and clearance of foreign particles has provided a 
rational approach to macrophage-specific targeting with nano-
carriers. Passive capture of colloidal carriers by macrophages offers 
therapeutic opportunities for delivery of antileishmanial drugs in 
leishmaniasis since it involves macrophages cells of the RES (fig. 2).  
Phagocytosis: a mechanism of passive targeting 
Phagocytosis ‘a biological phenomenon’ is carried out by specialized 
cells of the mononuclear phagocytic system (MPS) called 
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phagocytes. Phagocytosis is mediated by the adsorption of specific 
blood components (e. g. immunoglobulin IgG, complement C3b, and 
fibronectin) called opsonins and binding of pertinent receptors 
located on macrophages to the entity being phagocytosed. As the 
ingestion of moiety takes place, the phagocytic vacuole (or 
phagosome) fuses with one or more lysosomes to form mature 
phagolysosome (secondary lysosomes), and this occurs through a 
succession of transient fusion proceedings with early endosomes 
(EE), late endosomes (LE) and lysosomes (Ly). This maturation 
progression allows phagosomes to acquire some of their 
microbicidal properties and the ability to process antigens. All the 
way through evolution, intracellular pathogens have developed 
diverse strategies to avoid killing in phagolysosome [22]. The 
promastigote form of Leishmania alters phagosome maturation by 
inhibiting fusion with late endosomes and lysosomes. This allows 
these pathogens to reside in phagosomes displaying early 
endosome-like features that are not able to kill and degrade 
microorganisms. On the other hand, amastigote form of Leishmania 
seems to be able to survive in the harsh environment of 
phagolysosome. Thus uptake of drug loaded carriers by the RES 
system followed by digestion of carrier by lysosomal acid 
hydrolysase, subsequently releasing the drug may work in co-
ordination. This would allow the drug to exert selectively its 
therapeutic effect and thus eliminate the parasite. Primaquine, when 
loaded in polyisohexylcyano-acrylate [23] and poly alkyl 
cyanoacrylate [24] nano particles showed superior antileishmanial 
activity as compared with free drug. The drug-loaded polyisohexyl 
cyanoacrylate nano particles showed a 21-fold increase in 
antileishmanial activity as compared with the free drug when 
evaluated in vitro using J774G8 macrophage-like cells infected with L. 
donovani. Primaquine loaded poly (DL-lactide) nano particles were 
found to be 3.3 times more effective than that of the free drug in terms 
of amastigote suppression in the liver [25]. Moreover, these nano 
particles were found to be non-toxic [26]. Another study reports the 
potential application of biodegradable polymer methoxy poly-
(ethylene glycol)-b-poly (lactic acid) nano particles MPEG-PLA NPs 
loaded with doxorubicin and mitomycin C as a method for targeted 
drug delivery to macrophages with fewer side effects [27]. 
 
 
Fig. 2: Schematic representation of passive targeting to 
leishmaniasis infected macrophages of RES 
 
Factors facilitating passive targeting 
In the past few decades, many advances have been made in the field 
of delivery systems containing drugs against Leishmania parasite. 
This advancement in technology rekindles hope for treatment of the 
disease. Various drugs have been the key treatment for 
leishmaniasis, but to prevent the pharmacological and toxicological 
mani-festations of the drug before reaching the RES, there exists an 
urgent need to deliver the drugs in the immediate vicinity of the 
required site. The passive target ability attributed to drug carriers is 
due to the recognition of these exogenous particles either in intact or 
in the opsonized form by the phagocytic cells of the RES, and this sensing 
behavior is exploited to target macrophage-associated disease cell lines 
[28]. Passive targeting is being exaggerated by pathophysiological 
factors (inflammation/infection and enhanced permeation and retention 
effect) as well as physicochemical factors (size, surface charge, and 
molecular weight) of the drug delivery system.  
Inflammation/infection and enhanced permeation and 
retention (EPR) 
Macrophages are regulators of inflammation in many infectious 
diseases as they secrete a multitude of inflammatory mediators and 
hence serve as the potential pharmaceutical target for various 
animals and human diseases. Although, some of the microorganisms 
like Toxoplasma gondii, Leishmania sp, Mycobacterium tuberculosis, 
and Listeria monocytogenes have developed the potential ability to 
resist this phagocytosis activity, carrier-mediated delivery of 
antimicrobial agent (s) into pathogen-containing intracellular 
vacuoles in macrophages could be useful to eliminate these cellular 
reservoirs [29-30]. This could reduce side effects associated with the 
drug administration and also release of pro-inflammatory cytokines 
and at the same time will help to achieve therapeutic drug 
concentrations in the vacuoles of infected macrophages. Hence, nano-
systems designed utilizing above approach may be immensely useful 
in macrophage targeting of disease like leishmaniasis (table 2). 
Increase in permeability of blood vessels due to infectious diseases 
results in the leaky vasculature, allows migration of 10-500 nm 
diametric particles across the blood vessel walls and intestinal space 
[31]. The nature of the disease affects the porosity of the 
vasculature, allowing for control over the diffusion of the drug; the 
choice of a properly sized carrier would allow the drug to 
extravasate from the blood vessel. This phenomenon is termed as 
“Enhanced Permeation and Retention (EPR) effect” [32]. Drug 
carriers should, however, circulate in the blood long enough to 
provide acceptable accumulation of the active molecule in the area 
of interest. To overcome this dilemma sterically stabilized liposomes 
have been developed to provide long circulation of liposomes and to 
make the system more stable in biological surroundings. Sterically 
stabilized liposomes thus avoid their recognition from RES uptake, 
and this ‘stealth’ effect makes them long circulatory in nature. The 
adsorption of Silicone-glycol copolymers on the surface of liposomes 
was utilized for their steric stabilization [33]. These sterically 
stabilized vesicles showed enhanced half-life. In a similar study, 
sterically stabilized polyethylene glycol (PEG) coupled liposomes 
were developed and studied for the antileishmanial efficacy of 
camptothecin (CPT) in the free and liposomal form in vitro against L. 
donovani promastigote as well as in vivo in a murine model of VL. 
Treatment of infected mice intraperitoneally with free and liposomal 
CPT significantly reduced the hepatic parasite loads by 43 and 55%, 
respectively as compared with loads of untreated controls [34]. 
Size 
The depth of penetration in the target tissue has always been a 
problem with targeted drug delivery. It has been illustrated that 
after extravasation from the vasculature, the targeted carriers bind 
to the first few cell layers in retarding the entry of following carriers 
[35]. This phenomenon is correlated with the size of the nano vector 
and binding affinity of the targeting ligand. The bigger nanovectors 
and stronger binding ligands penetrate shorter distances. 
Chemotherapy and especially systemic administration of drugs is 
plagued by insufficient drug delivery to the desired site and toxic 
side effects, because there is practically no control over bio 
distribution of systemically administered drugs. The effectiveness of 
drug delivery systems can be manipulated by an alteration in their 
size, which can facilitate controlled release of the drug, modification 
of drug pharmacokinetics and biological distribution and also 
reduced drug toxicity. 
When novel liposomal formulation of meglumine anti-moniate 
consisting of reduced size vesicles was evaluated in dogs having VL, 
it was found that passive targeting of liposomes to the bone marrow 
of infected host was improved by the reduction in vesicular size to 
the nanoscale. In this study, the pharmacokinetics of antimonial 
drug was assessed in the blood and in organs of the mononuclear 
Kashaw et al. 
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phagocytic system for the liposomes of vesicular size 400 nm and 
compared with free drug and drug encapsulated large sized 
liposomes (mean diameter 1200 nm). The reduction in vesicle size 
from micrometer to nano size range exhibited direct passive 
targeting of liposomes to the bone marrow of dogs infected with VL 
[36]. Hence, the size of 150-250 nm may be considered appropriate 
to be actively phagocytosed by macrophages. Apart from size, a 
surface characteristic of the moiety also decides the degree of 
opsonization. The Greater hydrophilic surface of the system leads to 
decreased opsonization and phagocytic uptake. Miltefosine (MF) 
loaded albumin microparticles of size range 2-5 µm were prepared 
by spray drying method combined with thermal stabilizer. The 
formulation was found suitable to target the macrophages as 65% of 
RAW macrophages cells engulf MF microparticles within 90 min 
when administered parenterally. The microparticles also displayed 
less hemolytic toxicity as compared to free MF [37]. 
In a study by Nahar et al., PLGA nanoparticles (PNPs) encapsulating 
AmB were prepared by emulsion solvent evaporation method. The 
developed system was found to be in nanometric size (168 nm) and 
showed 85% inhibition against promastigote model and the activity 
of AmB as a plain drug, Ambisome and PNPs against L Donovani in 
intra-amastigote macrophage model showed 71.77%, 83.03% and 
84.06% inhibition respectively [38]. In another study Singh et al., 
evaluated the antileishmanial efficacy of Am B bearing 
polycaprolactone (PCL) microparticles. The microparticles were 
prepared, optimized and subjected to in vitro characterization for 
shape (spherically structured), particle size (9.83±1.12 micron), 
entrapment efficiency (43.54±3.98%) and in vitro drug release and 
revealed their efficacy against leishmanial parasites residing in 
macrophages [39]. 
Surface charge 
The charged phospholipids contained in liposomes greatly enhance 
their binding to the macrophages, which in turn are consequently 
engulfed by these cells. This offered a strategy for targeting VL based 
on the development of cationic liposomes composed of positively 
charged stearylamine-egg phosphatidylcholine-bearing drug 
liposomes (SA-PC liposomes). Both promastigote and intracellular 
amastigotes in vitro and in vivo were susceptible to SA-PC liposomes. 
A single dose of 55 mg of SA-PC liposomes/animal was able to 
significantly reduce the hepatic parasite burden by 85 and 68% 
against recent and established experimental VL, respectively, 
suggesting their strong therapeutic potential [40]. 
When drugs are administered in free form in the body, only a small 
fraction can reach the macrophages, and the remaining fraction of 
the drug may lead to toxic side effects. This serious problem has 
generated the need to develop strategies for selective and targeted 
delivery of drugs to the macrophages. Uptake of the carrier system 
by macrophages increases appreciably when a charge capable of 
interacting specifically with the surface of macrophages is 
incorporated. In a study by Alving et al., (1978), the research group 
found out that the efficacy of treatment was influenced by the lipid 
composition and charge of the liposomes. They observed that 
positively charged liposomes containing egg phosphatidylcholine 
were much less effective than negatively charged ones, whereas 
positively and negatively charged sphingomyelin liposomes were 
found equally effective. Liposomes containing phosphatidylserine 
(which were negatively charged, but also had a much higher charge 
density) were among the less-effective preparations. Furthermore, 
among the tested, liposomal formulations, most consistently 
efficacious liposomes contained highly saturated long-chain 
phospholipids (eg. dipalmitoyl phosphatidylcholine), cholesterol, 
and a negative charge [41].  
Concept of active targeting 
Active targeting redefines the biofate or natural distribution pattern 
of the drug carrier system with modification or manipulation of the 
surface of carriers so that it can be identified by specific cells. 
Binding of drug loaded carriers to target cells is facilitated by the use 
of ligands or engineered homing devices and thus enhances the 
receptor-mediated localization of drug. Leishmania parasite resides 
in intracellular phagolysosome and hence there is a need to target 
the drug delivery system intracellularly. Intracellular targeting is 
third order targeting and involves receptor-based ligand-mediated 
entry of a drug complex into a cell by endocytosis followed by 
lysosomal degradation of carrier leading to the release of drug.  
The uptake of leishmania promastigote by macrophages is a 
receptor-mediated process that involves the expenditure of energy 
by the macrophage, but not by the parasite. Due to the obligate 
intracellular nature of the pathogen, this organism expresses several 
different ligands on its surface that can interact with a variety of 
different macrophage receptors, to ensure its uptake by phagocytic 
cells. These include the receptors for complement, fibronectin, 
sugars (such as the mannose-fucose, galactosyl receptor) and others. 
Different receptors bind carrier molecules with different avidity. In a 
study by Banerjee et al. (1996), the mannose-grafted pentamidine 
isothionate liposomes were found to be the most effective, with 
85.1% reduction in splenic parasite load as compared with glucose-
grafted liposomes (65.9% reduction), galactose-grafted liposomes 
(45.1% reduction), uncoated liposomes (46.6% reduction) and free 
drug (18.5% reduction in splenic parasite load) when tested in L. 
donovani infected hamsters [42]. 
The intracellular localization of the pathogens in the diseases of 
microbial etiology such as VL necessitates the administration of 
relatively high doses of cytotoxic drugs thereby causing the side 
effects. The rational approach to the problem requires that drugs 
should be targeted to the macrophages in such a way that the 
interaction of the free drug with non-target tissues could be 
minimized [43]. Many approaches for targeting drugs to the 
macrophages have been developed. Although many carriers show a 
natural affinity towards the macrophages and are passively targeted 
to them, the inclusion of the macrophage receptor(s) specific ligands 
may significantly enhance the rate and extent of their uptake by the 
macrophages.  
These receptors are able to bind to modified lipoproteins, senescent 
and apoptotic cells, proteins, polysaccharides and a range of poly 
anionic molecules and control the activities such as activation, 
recognition and endocytosis [44]. 
Receptor mediated targeting strategy 
The surface of promastigote has phosphoglycans (lipo-phospho- 
glycans (LPG) and proteophosphoglycans (PPG) and gp63 molecules 
that serve as ligands for their attachment and subsequent entry in 
the macrophages [71]. CR1 and CR3 receptors are complementary 
receptors which facilitate phagocytosis of the promastigote and 
improve the survival of the parasite via preventing respiratory burst 
[72-73]. CR4, fibronactin receptors, mannose receptors and 
advanced glycosylation end product receptors are the other 
receptors engaged in phagocytosis. In case of amastigote, 
proteophosphoglycans are involved in the phagocytosis since 
lipophosphoglycan are absent [74]. CR3, Fc and mannose receptors 
are receptors on macrophages specifically for uptake of amastigote. 
Receptors present on the cell surface of macrophages are complex 
trans-membrane proteins, which mediate highly specific 
interactions between cells and their extracellular region. Receptors 
have highly specialized recognition sites with rigid structural 
requirements for binding signalling ligand. Exploiting a variety of 
macrophage cell receptors as therapeutic targets may prove to be a 
fascinating strategy for delivery and targeting of drugs with 
particulate nanocarriers [75]. 
Ligands are carrier associated surface group(s) which can 
selectively direct the carrier to the pre-specified site(s) housing 
appropriate receptor units and thereby serveing as ‘homing device’ 
of the carrier/drug. The interaction occurs due to their respective 
receptors localized on the cellular surface as showed in fig. 3. 
Further, the cellular machinery that drives receptor-mediated 
events is endocytosis, receptor-mediated endocytosis, clathrin 
linked endocytosis, ligand-mediated transcytosis, etc. 
The potential targeting moieties exploited for selective drug 
targeting may be widely classified into endogenous ligands, 
immunological ligands, glycol-conjugates and antibody conjugates. 
These include antibodies and their fragments, aptamer (protein 
Kashaw et al. 
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binding DNA), peptides, proteins, saccharides, hormones, glyco-
proteins, fusogenic agents and vitamins, especially folate. However, 
major concern is that the targeting ligand itself could elicit an 
immunogenic response in a patient although this issue is more 
prominent for antibodies. 
In a study by Kansal et al., Phosphatidylserine (PS) was used as 
ligand to target Leishmania-infected macrophages by developing 
Nano capsules (NCs) being doxorubicin (DOX). And, results opened 
the insight for efficient drug delivery, as PS-NCs-DOX, causing 
85.23% ± 4.49% inhibition of splenic parasitic burden whereas, NCs-
DOX and free doxorubicin caused only 72.88% ± 3.87% and 
42.85% ± 2.11% parasite inhibition, respectively, in Leishmania-
infected hamsters [76]. 
Lectin receptors 
Lectins belong to a class of proteins characterized by the ability to bind 
carbohydrates with high specificity. Design and development of 
potential carriers for cell specific delivery of therapeutics are 
immensely dependent on the selectivity of the carrier to the cellular 
receptors distributed variably at intracellular sites and on the surface 
of cellular systems. Lectin receptors present on macrophages 
constitute potential recognition sites for carbohydrate-mediated 
interaction between the cells and drug carrier bearing suitable site-
directing molecules. Banerjee et al., 1996 formulated different sugar-
grafted liposomes encapsulating pentamidine isothionate and their 
methoxy derivative tested in-vivo against reversible VL in hamsters. 
Sugar-grafted liposomes are encapsulating both the drugs were found 
to be more potent in comparison to plain liposomes encapsulating 
drug and the free drug [42]. 
Mannose receptors 
Macrophages express mannose-specific endocytotic lectin receptors 
that bind and internalize mannose-conjugated bio conjugates. The 
expression of this receptor is tightly modulated during monocyte/Mf 
differentiation and cellular activation. Receptor activity is dependent 
on the number of receptors present on the cell surface, the affinity of 
these receptors for the ligand, the rate of receptor internalization 
and recycling. Mitra et al. compared the antileishmanial property of 
a benzyl derivative of an antibiotic MT81 (Bz2MT81) in free, 
liposome-intercalated and mannose grafted liposome-intercalated 
forms in L. donovani infected hamsters [77]. Various formulations 
were administered subcutaneously at a dose equivalent to 7.5 
mg/kg (body weight) for 15 d at an interval of 3 d. In case of 
mannose grafted liposomes, the splenic parasitic inhibition was 
79.1%. Further, free and liposomal drug forms were less effective in 
reducing the parasite load in spleen (49.8 and 55.1% parasite 
suppression, respectively). In a similar study, Veera reddy et al. 
developed uncoated and mannose-coated lipid nanospheres of AmB. 
These formulations were administered to L. donovani-infected 
BALB/c mice at a dose of 5 mg/kg [61]. The same dose of Fungizone 
solution was also administered to separate mice as control groups. 
In liver and spleen, the mannose-anchored AmB lipid nanospheres 
reduced the parasitic burden by 95% and 94%, AmB lipid 
nanospheres reduced 90% and 85% and Fungizone reduced 82% 
and 69%, respectively. The tissue distribution studies suggested 
mannosylated nanospheres to distribute specifically more rapidly to 
liver and spleen. 
Thus, the mannosylated formulation can be deemed to have 
convincing prospectives in delivering antileishmanial drugs to 
parasite-infected macrophages. Selective delivery of liposomes may 
be performed by the mannose receptors on the surface of 
macrophages [77-80]. Fiani et al. (1998) performed ligand binding 
studies on J774 clone cells. The research group concluded that these 
cells differ primarily in their levels of mannose receptors on the cell 
surface, and there may be two levels of regulation. One in which 
receptor numbers being modulated by receptor synthesis and 
receptor degradation and the other in which the intracellular 
itinerary of the receptor is modulated [81]. 
 
 
Fig. 3: Schematic representation of active targeting to Leishmania-infected macrophages 
 
The development of amastigotes occurs in the phagolysosome of 
macrophages, and the effective targeting may be performed via the 
mannose lectin since it is localized at the surface of the 
macrophages. This may allow specific internalization of 
mannosylated ligands which are quickly transferred from endocytic 
vesicles to early endosomes (where receptor-ligand dissociation 
occurs) and then to the phagolysosome. The active targeting of CpG-
containing oligo deoxynucleotide (CpG-ODN) to macrophages was 
studied by incorporating it in mannose coated liposomes and 
injecting it in animals with VL as the model macrophage disease. A 
complete elimination of spleen parasite burden was achieved by 
mannosylated liposomal CpG-ODN in comparison to 62% and 81% 
parasite suppression by free and liposomal ODN formulations 
respectively in 60 d mouse model [82]. Kole et al. found that 
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mannosylated liposomes of doxorubicin were more effective than 
plain liposomes or free doxorubicin in the treatment of VL in L. 
donovani-infected BALB/c mice [83]. 
Emulsomes are nano emulsion pharmaceutical compositions 
comprising of a lipid core that is a solid or liquid crystalline phase 
and stabilized by at least one phospholipid envelope. These have 
been found suitable for the parenteral, oral, rectal, intranasal, or 
topical delivery of both fat-soluble and water-soluble drugs [84, 85]. 
Trilaurin based nanosized lipid particles (emulsomes) of Amb had 
been formulated and stabilized by soya phosphatidylcholine as a 
new intravenous drug delivery system for macrophage targeting. 
The system was modified via coating with the macrophage-specific 
targeting ligand O-Palmitoyl mannan (OPM). These OPM grafted 
emulsomes showed higher In-vitro efficacy in comparison to plain 
AmB emulsomes and AmB-Doc against L. donovani infected 
macrophages amastigotes system. At the same time OPM grafted 
emulosomes showed more efficient parasitic inhibition (PI), vis a vis 
73.7±6.7% in comparison to plain emulsomes (51.7±5.4%) and 
AmB-Doc (30.4±4.8%) when administered intracardially at alternate 
days to infected hamsters [65]. 
Mannosyl–fucosyl receptor 
A leishmanicidal drug, HPP-Rib encapsulated in a macromolecular 
carrier decorated with mannosyl residue was targeted to mannose-
fucose receptors of macrophages and tested in L. donovani-infected 
macrophages. It was revealed that 50% effective dose of HPP-Rib 
linked to the mannosylated polylysine was less than 7.5 x 10-6 M, 
whereas it was 3 x 10' M in the case of free HPP-Rib. It was also 
visualized that HPP-Rib bound to the polymer was found to be 50 
times more active than the free drug in killing the parasites [86]. 
Neo glycoproteins as a targeting tool are the cell adhesion molecules 
found on the cell surface and act as receptors for cell-to-cell and cell-
to-extracellular matrix adhesion. These molecules are required for 
the efficient migration of inflammatory cells such as neutrophils and 
monocytes into inflamed organs and generation of the host response 
to infections. In this context, fucose human serum albumin (HSA) 
was studied to determine the characteristic recognition system 
involved in the receptor-mediated endocytosis. Fucose HSA 
illustrated strong binding affinity and uptake by the macrophages, 
and the binding was specific for L-fucose and D-mannose. 70% and 
60% of fucose-HSA was found to be localized in liver and liver 
lysosomes respectively. At the same time, its uptake was 30 folds 
more via liver macrophages (kuffer cells) in comparison to 
hepatocytes. The result also suggested that fucose HSA has a greater 
affinity than mannose HSA for both mannose and fucose receptors 
and even a single type receptor [87]. In the same pathway, 
Chakraborty et al. performed binding experiments of methotrexate 
coupled to mannosyl-BSA. Studies indicated that conjugation did not 
decrease the affinity of neoglycoprotein for its cell surface receptors 
and was efficiently taken up by the mannosyl receptors present on 
the macrophages. The intracellular amastigotes of L. donovani in 
mouse peritoneal macrophages were eliminated 100 times more 
efficiently by the methotrexate neoglycoprotein conjugate compared 
to free drug. Furthermore, this inhibitory effect was found to be 
directly proportional to the density of sugar on the neoglycoprotein 
carrier. Moreover, the drug-conjugate reduced 85% of spleen 
parasite burden in a 30 d murine model illustrating that conjugate 
binds specifically to the macrophages. This may be accompanied 
with internalization in lysosomes and subsequent release of the 
active drug in the proximity of Leishmania parasite [88]. 
Promastigotes of L enrietti have been tested with neoglycoproteins 
to ascertain the existence of endogenous lectins. Agglutination test 
revealed that promastigotes of human leishmania react with neo-
glycoprotein N-acetyl-D-galactosamine-para-aminophenyl-bovine 
serum albumin (glcNAc-BSA), since the promastigotes of L. enrietti 
were agglutinated by the D-mannose-bovine serum albumin (man-
BSA) while amastigotes form failed to react. These reactions were 
inhibited by sugars N-acetyl-beta-D-glucosamine, N-acetyl-beta-D-
galactosamine and alph-D-Mannose as was confirmed by the 
fluorescence tests. Results demonstrated the calcium-dependent 
lectins to be expressed on the surface of leishmania parasite and 
accessible to glcNAc-BSA [89]. To follow Sarkar et al., (1997) 
exploited mannose-HSA for active targeting of muramyl dipeptide 
(MDP) to macrophages of VL. Mannose-HSA-MDP was found to be 
50 times more effective than free MDP against L. donovani inside 
peritoneal macrophages. At the same time, a 95% reduction in spleen 
parasite burden in 60 d infected murine model after 4 d therapy was 
obtained and this was bestowed to be dependent on the physiologic 
generation of NO induced by IFN-gamma and TNF–alpha [90]. 
Scavenger receptors 
Scavenger receptors are exclusively expressed on liver endothelial cells 
and these high binding sites are conserved on macrophages. 
Macrophages mediate the uptake of a variety of polyanionic 
proteins/ligands or macromolecular complexes. Antimony loaded 
liposomes (Sb-LP) made up of phosphatidylserine have been found to be 
preferentially taken up by macrophages scavenger receptors. Sb-LP 
were 16-fold more effective (IC50-514.11 mM) than the free drug (IC50-
5225.9 mM) against L. chagasi infected macrophages. This binding and 
uptake of the Sb-LP were found to be energy dependent [91]. 
Several classes of scavenger receptors provide broad ligand specificities 
such as oxidized proteins and polyanions. They recognize a number of 
structurally diverse polyionic macromolecules such as charged modified 
proteins (eg. acetylated or oxidized LDL, maleylated serum albumin), 
polysaccharides (eg fucoidin, dextran sulphate), polynucleotide’s (eg. 
polyguanylic and polyinosnic acids), certain acidic phospholipids 
(phosphatidylserine), polyvinyl sulphate and bacterial 
lipopolysaccharides. Methotrexate (MTX) conjugated with maleylated 
bovine serum albumin (MBSA) was administered to the L. Mexicana 
infected hamsters. Due to localized infection created in foot pads, 10 
folds higher swelling than normal foot pads was obtained because of 
multiplication of protozoa. Free drug MTX exhibited no cure whereas 
MBSA-MTX treatment transformed the foot pads to normal size [92]. 
Similarly, Nieto et al. determined the pharmacokinetics/toxicities (in 
dogs) and antileishmanial efficacy (in L. donovani infected BALB/c mice) 
of plain niosomes (NIV) and dextran coated niosomes (NIV-dextran) 
encapsulating antimonial drug sodium stibogluconate (SSG) after 
administration of a single intravenous dose [51]. The NIV-dextran form 
significantly modified the pharmacokinetics of the drug, whereas the 
free drug and NIV form showed similar pharmacokinetic profile. 
Monoclonal antibodies 
Antibodies are highly selective for the relevant antigen, and this 
feature can be exploited for precise delivery of drugs to desired 
tissues. Moreover, it is now possible to create monoclonal 
antibodies, i.e., antibodies designed to be specific for almost any 
substance, obtained from a single clone of an immune cell. They can 
be engineered in several ways in order to meet specific 
requirements from different biological environments. Antibodies are 
proteins composed of IgG, which contains binding fragment (Fab, 
responsible for specific antigen binding) and a complement-fixing 
fragment (Fc, responsible for fixing complement for in vivo biological 
response). Recombinant antibody technology allows for the 
preparation of a library of antibodies from which the ones with the 
required properties can be selected. Antibody fragments lacking the 
Fc-region, e. g., Fab′ or single-chainFv (scFv), can be used to avoid 
recognition by Fc receptor-bearing cells of the RES [93]. 
Recent developments in liposomal technology have made it feasible 
to investigate the therapeutic applications involving site-specific 
delivery mediated by antibodies. Liposomes appended with 
antibodies or their fragments on their surfaces are known as 
immuno- liposomes. Immuno liposomes have been used extensively 
as a drug delivery strategy towards macrophages for the treatment 
of VL. Anti-target antibodies having specific avidity to target has the 
ability to direct liposomes to the desired target. Targeting of 
doxorubicin to L. donovani-infected BALB/c mice was studied by 
Mukherjee et al. Doxorubicin was incorporated in immuno- 
liposomes prepared by grafting F(ab)¢2 fragment of anti-51-kDa 
antibody onto the liposomal surface [94]. The results showed that at 
a dose of 250 mg/kg/day administered for 4 consecutive days, there 
was a complete elimination of splenic parasite burden by 
doxorubicin loaded immuno- liposomes. A reduced toxicity of 
doxorubicin upon encapsulation in liposomal formulations was also 
visualized. In another approach, liposomes grafted with IgG 
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(immuno- liposomes) resulted in superior efficacy than free IgG and 
plain liposomes in clearing L. donovani parasites from the 
macrophages, owing to their increased uptake by the FcR in 
macrophages. On incubation of liposomal IgG with macrophages 
infected with different strains of L. donovani (UR6, AG83 and GE1 
strains), the induced macrophage activation suppressed the parasite 
burden of different strains to an extent of 60%, 50% and 45%, 
respectively [95]. Sitamaquine encapsulated PLGA-PEG nanoparticle 
(NP) attach with antibody to CD14 to target macrophage of infected 
tissues against leishmaniasis have been developed. The evaluation 
parameter shows significant inhibition of amastigotes in the splenic 
tissue with PLGA-PEG encapsulated sitamaquine as compared to the 
conventional (89.01±6 verse 71.39±12) [96]. 
Interferon-γ 
Macrophage-specific targeting exploiting interferon-α may be a 
fascinating approach to eradicate intracellular parasites by 
increasing the localized manifold concentration of the drug and by 
reducing contraindicated manifestations resulting from systemic 
drug effects. In a study by Kole et al. (1999), the research group 
encapsulated doxorubicin in mannosylated liposomes and further 
conjugated with INF-γ. The combined chemotherapy resulted in 
complete elimination of splenic parasite burden. Further, mRNA 
levels were also analysed in infected spleen cells, and the targeted 
drug delivery together with IFN-a resulted in reduced levels of IL-4, 
increased level of IL-12 and production of inducible nitric oxide 
synthase. Such combination chemotherapy has proved to be a 
possible substitute for the cure of VL [97]. 
Tuftsin 
Tuftsin a tetrapeptide (Thr-Lys-Pro-Arg) has been found to 
participate in several biological functions associated with the 
immune system. It is generated in the body from a specific cytophilic 
fraction of the protein (leukokinin) through a two-step enzymatic 
processing mechanism [98, 99]. The tetrapeptide enhances the 
phagocytic activity of monocytes and macrophages [100, 101] 
Specific binding sites for tuftsin have been revealed to exist on 
macrophages [102]. Tuftsin exclusively binds to macrophages and 
potentiates their natural killer activity against pathogens [103]. This 
makes tuftsin an attractive candidate to be used as a ligand for 
targeting drugs to various macrophage-related diseases. Tuftsin-
based targeting of sodium stibogluconate (SSG) loaded liposomes 
was studied by Guru et al. in L. donovani infected hamsters for VL 
[104]. The findings indicated that encapsulation of SSG in tuftsin-
bearing liposomes significantly enhanced the drug efficacy against L. 
donovani infection. In a similar study, the antileishmanial activity of 
AmB was enhanced by encapsulating the drug in liposomes. This 
efficacy was further increased by grafting tuftsin on the liposomal 
surface. The tissue distribution studies also showed higher and 
faster uptake of tuftsin-grafted liposomes from the circulation as 
compared with non-grafted liposomes since almost all the tufstin 
grafted liposomes were cleared within 1 hr of administration [105]. 
Miscellaneous factors to promote macrophage to achieve 
targeting 
Multiple dosing 
The dosing strategy is a vital parameter to achieve desired 
therapeutic effect. In this context multiple dose pharmacokinetics 
and parasite inhibition (PI) of a liposomal formulation of meglumine 
antimoniate in bone marrow of dogs naturally infected with the L. 
chagasi was studied. Results demonstrated an increase in antimony 
concentration from 0.76µg/kg to 2.07µg/kg after 4 d therapy. 
Though complete elimination of the parasite was not achieved yet 
parasite load was significantly reduced [106]. In a study by Mullen et 
al., nonionic surfactant vesicle formulation of sodium stibogluconate 
(SSG-NIV) efficacy was compared with several formulations of AmB 
(i.e., Ambisome, Abelcet and Amphocil) in L. donovani-infected 
BALB/c mice murine model of VL. Multiple doses of AmBisome, 
Abelcet and Amphocil, showed different degrees of suppression in 
liver and spleen parasitic burden, with Abelcet having the lowest 
activity. AmBisome and Amphocil showed significant parasitic 
suppression in bone marrow. In case of acute infection model, 
single-dose treatments with SSG-NIV, SSG solution, or AmBisome 
were equally effective against liver parasites. SSG-NIV and Am-
Bisome significantly suppressed parasites in bone marrow and 
spleen, with SSG-NIV treatment being more suppressive. On the 
other hand, free-SSG treatment failed to suppress spleen or bone 
marrow parasites. In the case of chronic infection model, the single 
dose AmBisome was less effective at all three sites of infection 
whereas single dose SSG-NIV was less effective in the spleen [50]. 
Polymeric conjugation 
Polymer–drug conjugates have been used for passive targeting to 
macrophages. The strategy has exhibited potential in 
antileishmanial chemotherapy and modified the bio distribution of 
antileishmanial drugs (such as AmB) that were otherwise toxic for 
mammal cells when administered with water [107]. AmB, when 
conjugated with N-(2-hydroxypropyl) methacrylamide (HPMA) 
copolymer through a degradable GlyPheLeuGly linker, showed 99.6 
and 93.8% inhibition in hepatic parasite burden at a dose of 3 and 1 
mg/kg (body weight), respectively, when administered intravenously 
to L. donovani-infected BALB/c mice. Ambisome was taken for 
comparison, which showed 99.9% PI at the same doses [108].  
Nan et al., (2004) studied the bio distribution pattern and evaluated 
antileishmanial activity of aminoquinoline analogue, NPC1161 upon 
conjugation with HPMA copolymer. HPMA copolymer-NPC1161, 
containing N-acetylmannosamine (ManN) in the side chains, were 
synthesized. In vivo studies in L. donovani-infected BALB/c mice 
showed that HPMA-NPC1161-ManN was more effective than plain 
HPMA-NPC1161 conjugates [70]. HPMA copolymers containing 
ManN in the side chains could potentially reduce the toxicity and 
increased the efficacy of antileishmanial drugs for the treatment of 
VL. Similarly, Kozan and co-workers (2002) coupled Methotrexate 
(MTX) with different synthetically branched polypeptides such as 
poly [Lys (DL-Alam)](AK), poly[Lys(Seri-DL-Alam)](SAK), poly[Lys 
(DL-Alam-Leui)](ALK) and poly[Lys(Glui-DL-Alam)] (EAK). Midest 
of these conjugates, MTX-ALK produced the most encouraging data, 
with 95% parasitic inhibition in the liver as compared with free MTX 
(42% PI) when 5 injections (100 µg of MTX/injection) were 
administered intraperitoneally. Furthermore, the covalent bond 
between the carrier and the drug was observed to be crucial for its 
activity [109]. 
CONCLUSION 
The drug discovery pipeline for the treatment of leishmaniasis is 
imbalanced and still requires improved control tools. Along with 
efforts to find new compounds, resources availability is essential at 
this crucial stage of drug development. Novel therapies are the 
current hopes and have been promising with the pioneering of 
AmBisomes, for the treatment of VL. The formulation exhibits 
reduced toxicity, shorter treatment period and effective response to 
a single dose; but limits itself to a fraction of the population owing to 
its unaffordable cost. With advances in the development of drug 
delivery systems, a new era in the treatment of leishmaniasis has 
begun. The use, of drug carriers (i.e., liposomes, niosomes, 
emulsions, micro/nano particles) to efficiently deliver the 
antileishmanial agents inside the cells infected with leishmania 
parasite has been supported by numerous studies and are able to 
modify the distribution of an associated drug substance. These 
approaches seek to overcome drug resistance by more efficient 
delivery to target cells and in some cases by concomitant avoidance 
or inhibition of drug efflux mechanisms. However, owing to their 
complexities, site directed drug delivery systems such as ligand 
directed carriers undoubtedly cost more in development and 
manufacturing than conventional therapeutic agents. The resulting 
higher prices may be acceptable if the increase in cost can be 
minimized and if the performance of these drug delivery systems is 
increased sufficiently thereby reducing the treatment period and 
cost to produce overall savings to the healthcare system.  
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